about our programs

Portage has built a portfolio of six technology platforms initially yielding 14 candidates that uniquely target different cancer resistance pathways.

We’re leading scientists and clinicians through the development of immunotherapies that augment responses in immunogenic tumors and help initiate a response in non-immunogenic tumors. The flagship platform within our portfolio is our small molecule adenosine inhibitors (PORT-6, PORT-7, PORT-8 and PORT-9), which represent a comprehensive exploration of how targeting the adenosine pathway could improve response in multiple indications.  See current progress on our programs below.

Pipeline

There is a significant unmet need to better serve patients who do not respond to existing checkpoint inhibitors. We seek novel treatments to improve responses to these therapies. 

iNKT engagers

PRODUCT
TECHNOLOGY
ASSET
INDICATION
STAGE
PORT-2
TECHNOLOGY
iNKT Engagers
Liposomal Formulations
ASSET
IMM60
INDICATION
Refractory NSCLC & Melanoma
STAGE
Phase 1
PORT-2
TECHNOLOGY
iNKT Engagers
Liposomal Formulations
ASSET
IMM60 + Keytruda®
INDICATION
NSCLC & Melanoma
STAGE
Phase 1
PORT-2
TECHNOLOGY
iNKT Engagers
Liposomal Formulations
ASSET
IMM60
INDICATION
Refractory Melanoma
STAGE
Phase 2 *
PORT-2
TECHNOLOGY
iNKT Engagers
Liposomal Formulations
ASSET
IMM60 + Keytruda®

Collaboration withMerck Logo

INDICATION
PD-L1 Pos NSCLC
Front line
STAGE
Phase 2 *
PORT-2
TECHNOLOGY
iNKT Engagers
Liposomal Formulations
ASSET
IMM60 + Keytruda®

Collaboration withMerck Logo

INDICATION
PD-L1 Pos NSCLC 2nd line
STAGE
Phase 2 *
PORT-2
TECHNOLOGY
iNKT Engagers
Liposomal Formulations
ASSET
IMM60 + Keytruda®

Collaboration withMerck Logo

INDICATION
PD-L1 Neg NSCLC
STAGE
Phase 2 *
PORT-3
TECHNOLOGY
iNKT Engagers
PLGA Co-formulations
ASSET
IMM60 / NY-ESO-1
INDICATION
Solid Tumors
STAGE
Phase 1

* Trial paused  in 2023

adenosine inhibitors

PLATFORM
TECHNOLOGY
ASSET
INDICATION
STAGE
PORT-6
TECHNOLOGY
A2AR Inhibitor
ASSET
TT-10
INDICATION
A2A & A2B High Solid Tumors
STAGE
Phase 1a
PORT-7
TECHNOLOGY
A2BR Inhibitor
ASSET
TT-4
INDICATION
A2A & A2B High Solid Tumors
STAGE
Phase 1a*
PORT-7
TECHNOLOGY
A2BR Inhibitor
ASSET
TT-4
INDICATION
A2B High
Solid Tumors
STAGE
Phase 1b*
PORT-6
TECHNOLOGY
A2AR Inhibitor
ASSET
TT-10
INDICATION
A2A High
Solid Tumors
STAGE
Phase 1b*
PORT-6
combo
TECHNOLOGY
A2AR Inhibitor
ASSET
TT-10 + Keytruda®

Collaboration withMerck Logo

INDICATION
A2A High
Solid Tumors
STAGE
Phase 1b*
PORT-7
combo
TECHNOLOGY
A2BR Inhibitor
ASSET
TT-4 + Keytruda®

Collaboration withMerck Logo

INDICATION
A2B High
Solid Tumors
STAGE
Phase 1b†
PORT-6/7
combo
TECHNOLOGY
A2AR Inhibitor + A2BR Inhibitor
ASSET
TT-10 + TT-4
+/- Keytruda®

Collaboration withMerck Logo

INDICATION
A2A/A2B High
Solid Tumors
STAGE
Phase 1b†

† Planned trial to be initiated in 2024

Additional Programs in Development

Portage’s pipeline also includes antibodies, small molecules and protein therapeutics delivered by novel intratumoral formulations (PORT-1), nanolipogels (PORT-4), and virus-like particles (PORT-5) *

PLATFORM
TECHNOLOGY
ASSET
INDICATION
STAGE
PORT-4
TECHNOLOGY
Nanolipogel Co-Formulations (NGLs)
ASSET
SAUG 1 (PD1 + VEGF TKI)
INDICATION
Solid Tumors
STAGE
Preclinical
PORT-4
TECHNOLOGY
Nanolipogel Co-Formulations (NGLs)
ASSET
SAUG2 (PD1 + CTLA4)
INDICATION
Solid Tumors
STAGE
Preclinical
PORT-5
TECHNOLOGY
VLP-STING
ASSET
STIM1 + approved agent
INDICATION
Solid Tumors
STAGE
Preclinical

* Portage Biotech has  a 70% economic interest in PORT-4 (SAUG-1 and SAUG-2); and a 44% economic interest in PORT-5 (STIM1), which is being advanced in partnership with Stimunity.